VenoStent
venostent.com
Actively hiring
3D Printers & Additive Manufacturing
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$19.1M
6 rounds on record
Latest round
$16.1M
Series A · Jul 2023 · 3 yr ago
Backers
3
Health Wildcatters, Y Combinator
The money's age
Long since its last round
38 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 10
Took on debt financing $10M · SEC Form D
Jul 5, 2023
Raised a round Series A $16.1M · SEC Form D
Jan 29, 2021
Raised a round Seed $2.2M · SEC Form D
Jun 2020
Went through Y Combinator
May 26, 2020
Raised a round Convertible Note $515k · SEC Form D
Jun 25, 2019
Raised a round Venture round $264k · SEC Form D
Mar 7, 2018
Took on debt financing $70k · SEC Form D
2017
Founded
Tractionpublic signals, read monthly
Web presence
top 7%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Debt Financing | Apr 2026 | $10M | — | SEC Form D |
| Series A | Jul 2023 | $16.1M | — | SEC Form D |
| Seed | Jan 2021 | $2.2M | — | SEC Form D |
| Convertible Note | May 2020 | $515k | — | SEC Form D |
| Venture round | Jun 2019 | $264k | — | SEC Form D |
| Debt Financing | Mar 2018 | $70k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | VenoStent, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Geoffrey LucksExecutive Officer, DirectorSEC Form D
Timothy BoireExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Health Wildcatters 
Y Combinator 
Good Growth Capital Similar startupsby what they do, their industry and backers
Polyuse develops 3D printing technologies for the construction industry and advocates "coexisting construction with people and technology"…
Advanced medical devices for the treatment of metabolic diseases.
Phase3D’s software brings real-time analytics to additive manufacturing—improve print quality, reduce waste, and catch errors early with…
Roboze builds industrial three dimensional printers for high performance polymers. Its machines print parts that replace metal in robotics…
Colibrium Additive, a GE Aerospace company, leads the additive manufacturing industry with innovative technology in metal 3D printers…
Chromatic 3D Materials delivers advanced elastomer materials and 3D printing solutions.
Overview
Patients & Providers How SelfWrap Works Company News Clinical Trial Follow us for updates: LinkedIn Aiming to Improve the Lives of Patients Undergoing Vascular Surgery About VenoStent A Clinical-Stage Therapeutic Medical Device Company We're a clinical-stage therapeutic medical device company that's developed finely-tuned, bioabsorbable wraps intended to improve outcomes for the 5 million vascular surgeries performed each year.
News
VenoStent: $20 Million Series A Raised To Develop Therapeutic Device For Improving Dialysis Patient Outcomes
VenoStent, a clinical-stage medical device company developing a novel therapeutic device for improving dialysis patient outcomes, announced that it closed an additional $4 million from Norwest Venture Partners to round out its Series A financing at $20 mi
Read more
Report
VenoStent: $16 Million Closed To Develop Bioabsorbable Wraps For Improving Outcomes For Hemodialysis Patients
VenoStent - a clinical-stage, venture-backed, therapeutic medical device company developing bioabsorbable wraps for improving outcomes for hemodialysis patients - recently announced that they have been granted Investigational Device Exemption (IDE) from t
Read more
Report
VenoStent Completes $16M Series A Financing, Receives IDE Approval from FDA to Begin US Trial
VenoStent, Inc., a clinical-stage, venture-backed, therapeutic medical device company developing bioabsorbable wraps to improve outcomes for hemodialysis patients, has announced that they have been granted Investigational Device Exemption (IDE) from the F
Read more
Report
Report
The dangers of the SPAC speculation wave
Here's a story about the down side of SPACs. (Also: why metal cans are sexy)
Read more
Report
VenoStent Announces $2.3M in Seed Funding to Transform Vascular Access Surgery for Hemodialysis Patients
/PRNewswire-PRWeb/ -- VenoStent, a Houston-based advanced materials company, today announced $2.3M in seed funding. The company leverages its unique polymer...
Read more
Report
People
Geoffrey Lucks
Executive Officer, Director
Timothy Boire
Executive Officer, Director
Kulika Weizman
Director
Joel Whitley
Director
Jim Monsor
Director
Robert Crutchfield
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Nashville
United States
HQ
Financials
Total raised
$29.2M
Latest round
Debt Financing
Funding rounds
6